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The Effect of Commercial Tests for Aneuploidy Screening Using Cell-free Fetal DNA
on Rates of Invasive Testing in Clinical Practice
Adetola Louis-Jacques, Courtney Burans, Sara Robinson, Elizabeth Schofield, Joanne Quinones, John Smulian, Meredith Rochon
INTRODUCTION:
In the past two decades, numerous strategies for the detection of fetal 
aneuploidy have been developed, although definitifve diagnosis is possible only 
through the use of invasive procedures. In the fall of 2011, non-invasive tests 
for the diagnosis of common aneuploidies first became commercially available 
for the diagnosis of common trisomies and sex chromosome abnormalities. 
These tests work by identifying cffDNA in maternal blood with a high degrees 
of sensitivity and specificity, and have the advantage of providing the patient 
with highly accurate information without the discomfort or risk of an invasive 
procedure. The purpose of this study is to characterize the use of cffDNA testing 
at our institution and to see how the introduction of these tests has affected the 
rate of invasive procedures performed over time.  
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METHODS:
 •  Retrospective cohort study of all women undergoing cffDNA testing and/
or invasive testing for aneuploidy through Lehigh Valley Health Network 
Maternal Fetal Medicine practice from 12/1/2011 – 12/30/2012.  
	 	 –		Consistent with ACOG guidelines, invasive testing for aneuploidy (amniocentesis 
and CVS) is available to all women. 
	 	 –		CffDNA testing became available in late December 2011 in our practice and 
was offered only to women at high risk for aneuploidy based on maternal 
age, abnormal screening results, abnormal ultrasound findings, and/or family/
personal history of aneuploidy. 
	 	 –		All women underwent genetic counseling prior to invasive or cffDNA testing.
	 	 –		Women with positive cffDNA results were  strongly encouraged to undergo 
invasive testing to confirm results. 
 •  Women undergoing invasive procedures  and cffDNA testing during the 
study period were identified by review of a MFM clinical and ultrasound 
databases. Only women undergoing invasive testing for aneuploidy 
detection were included in the analysis. 
 •  Medical records were reviewed for baseline characteristics, indications 
for testing, test results and pregnancy outcomes. Neonatal records were 
reviewed when available.
 •  Descriptive statistics were generated for baseline characteristics and test 
indications. Chi square was used to compare the rate of change in invasive 
procedures and utilization of cffDNA over time.
CONCLUSIONS:
Our study provides some information on the use of new commercial tests for 
aneuploidy screening using cffDNA in clinical practice in a non-research setting. The 
new commercial tests available for aneuploidy screening using cffDNA were rapidly 
incorporated into clinical practice and are associated with decreased use of invasive 
testing for aneuploidy.
ABSTRACT:
Objective: TTo determine the effect of new 
commercial tests for aneuploidy screening 
using cell free fetal DNA (cffDNA) on rates of 
invasive testing.
Study Design: Commercial aneuploidy 
screening tests using cffDNA were first offered 
at Lehigh Valley Health Network Maternal 
Fetal Medicine in late December 2011. All 
patients offered cffDNA testing were at high 
risk for fetal aneuploidy defined as advanced 
maternal age, abnormal aneuploidy screening, 
abnormal ultrasound findings and/or personal/
family history. Data regarding cffDNA test 
rates, invasive testing rates (amniocentesis 
and CVS) and indication for testing were 
collected. Invasive testing indications were 
further categorized into testing for aneuploidy 
or for other indications. Chi square was used 
to compare rates of invasive testing before and 
after introduction of cffDNA testing.
Results: 365 patients underwent cffDNA 
testing from 12/1/2011 to 12/30/2012. The 
rates of invasive testing overall and invasive 
testing for aneuploidy both decreased 
significantly after introduction of cffDNA 
testing as compared to before (P<0.001). The 
difference in the number of invasive tests over 
time was due to a decrease in procedures for 
aneuploidy testing (Figure 1). The number of 
cffDNA tests increased significantly from the 
first half of 2012 to the second half of 2012 
(P<0.001).
Conclusion: The new commercial tests 
available for aneuploidy screening using cffDNA 
were rapidly incorporated into clinical practice 
and are associated with decreased use of 
invasive tests. 
Table 1. Baseline Characteristics of Women Undergoing 
Cell-free Fetal DNA Testing*
Mean maternal age (years) 32.3±6.5
Advanced maternal age 52%
Ethnicity 
   Caucasian 72%
   Black 7%
   Asian/Indian 6%
   American Indian 2%
   Arabic 1%
   Mixed 2%







High school graduate 89%
College graduate 42%





* Not all characteristics available for all subjects
Data in n (%), mean +SD or median (range). GA, gestational age.
Table 2. Primary Indications for Cell-free                      
 Fetal DNA Testing
AMA only 18%
Abnormal screen only 29%
Abnormal ultrasound only 37%
Abnormal screen and abnormal ultrasound 13%
History indicated 2%
Unspecified 1%
Data are in n (%). 
RESULTS:
 •  365 patients underwent cffDNA testing from 12/1/2011 to 12/30/2012.  
 •  The number of cffDNA tests increased significantly from the first half of 2012 to the second half of 2012 (143 vs. 222, P<0.001).
 •  Rates of invasive testing for aneuploidy decreased significantly from 2011 (before cffDNA) to 2012 (after cffDNA), p<0.0001.
Figure	1.	Volume	of	invasive	testing	for	aneuploidy	and	cell-free	fetal	DNA	diagnostic	
tests	for	first	year	cell-free	fetal	DNA	testing	was	offered
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